IPCA Laboratories logo

IPCA Laboratories results

NSE: IPCALABBSE: 524494Pharmaceuticals & BiotechnologyMid Cap

Last close ₹1,953.30up ₹49.80 (2.62%)BSE ₹1,951.25

Share price at the NSE close on 23 Oct 2026. Previous close ₹1,903.50.

52-week range of traded prices to 23 Oct 2026
₹1,251.60Low, 24 Oct 2025₹2,038.00High, 18 Sep 2026
Market cap
₹49,556 Cr229th largest listed
P/E
37.8
P/B
6.1
Dividend yield
0.31%
ROE
17.4%
ROCE
17.6%
Debt to equity
0.07
Volume, NSE
3,18,78151.9% delivered

Q1 results, quarter to Jun 2026

Consolidated: the company and its subsidiaries together. ₹ crore.IPCA Laboratories annual results and balance sheet

Revenue
₹2,788 Cr+20.8% on a year ago · +16.7% on the quarter before
Operating profit
₹670 Cr+60.8% on a year ago · +38.4% on the quarter before
Net profit
₹424 Cr+82.2% on a year ago · +38.3% on the quarter before
Earnings per share
₹15.84+72.4% on a year ago · +34.4% on the quarter before
Operating margin
24.0%
Net margin
15.2%

From revenue to net profit, ₹ crore

  1. Revenue2,788
  2. Materials and goods−797
  3. Employee costs−602
  4. Other expenses−720
  5. Operating profit670
  6. Depreciation−111
  7. Other income+25
  8. Finance costs−12
  9. Profit before tax572
  10. Tax−149
  11. Joint ventures+1.5
  12. Net profit424

IPCA Laboratories results by quarter

Consolidated: the company and its subsidiaries together. Latest quarter to Jun 2026. Results for the quarter to Sep 2026 are due by 14 Nov 2026, 45 days after it ends.Results filings and date

Revenue and net profit by quarter, ₹ crore

  • Revenue
  • Net profit

Operating and net margin by quarter, per cent

  • Operating margin
  • Net margin
₹ croreSep 2021Q2Filed 13 NovDec 2021Q3Filed 14 FebMar 2022Q4Filed 25 MayJun 2022Q1Filed 11 AugSep 2022Q2Filed 12 NovDec 2022Q3Filed 14 FebMar 2023Q4Filed 29 MayJun 2023Q1Filed 10 AugSep 2023Q2Filed 13 NovDec 2023Q3Filed 15 FebMar 2024Q4Filed 31 MayJun 2024Q1Filed 14 AugSep 2024Q2Filed 14 NovDec 2024Q3Filed 13 FebMar 2025Q4Filed 16 JunJun 2025Q1Filed 11 AugSep 2025Q2Filed 13 NovDec 2025Q3Filed 13 FebMar 2026Q4Filed 29 MayJun 2026Q1Filed 13 Aug
Revenue from operations1,5441,4301,2891,5861,6011,5461,5121,5882,0342,0532,0332,0932,3552,2452,2472,3092,5572,3932,3882,788
1,1791,1231,0701,3171,3401,3301,3311,2801,7131,7221,7111,7001,9131,7821,8181,8922,0121,8591,9052,119
Materials and goods bought544499426579575562591515678697686643759668708692782658692797
Employee costs296284298323319318327358426459466488510485501543538546533602
Other expenses338340346415446450412407609566559569645629609658692655680720
Operating profit before depreciation366308219269261216181308321331322393441463429416545533484670
Operating margin23.7%21.5%17.0%17.0%16.3%14.0%12.0%19.4%15.8%16.1%15.8%18.8%18.7%20.6%19.1%18.0%21.3%22.3%20.3%24.0%
Depreciation and amortisation575961626467706990100989910098100100103108107111
Other income1813152236313645392219212620263328209425
Finance costs11379111831443329242317221920182012
Profit before one-off items and tax326261170223224169129252225221213290345368333331450428450572
One-off items00000000068−137000−2050−5818−460
Profit before tax32626117022322416912925222528977290345368128331392446404572
685728747754488688667491999162961088295149
Tax rate20.9%22.0%16.7%33.3%34.4%31.7%37.4%34.0%39.0%22.9%96.2%31.5%28.8%24.6%48.6%29.1%27.6%18.4%23.5%26.1%
Share of profit of joint ventures and associates−5−5−9−3−1−6−3−2−1−2−200−1−2−2−30−31
25219913214514611078164136221119924627664233281364307424
Other comprehensive income−3122−362−1−11−80−5−13−7511−127−20
Total comprehensive income25020013314714311680163136222−720024126457238292363334404
Net margin16.3%13.9%10.2%9.2%9.1%7.1%5.2%10.3%6.7%10.8%0.1%9.5%10.4%12.3%2.8%10.1%11.0%15.2%12.8%15.2%
Net margin without joint ventures and associates16.7%14.2%10.9%9.4%9.2%7.5%5.4%10.5%6.8%10.8%0.1%9.5%10.4%12.4%2.9%10.2%11.1%15.2%13.0%15.2%
Earnings per share₹9.87₹7.76₹5.13₹5.64₹5.67₹4.25₹3.02₹6.42₹5.72₹7.09₹2.35₹7.58₹9.05₹9.78₹2.67₹9.19₹11.14₹12.86₹11.79₹15.84
Earnings per share in rupees, restated for later splits and bonuses.

Filed results, as an XML file each

16 earlier filings